Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis.
Daptomycin
Healthcare-associated meningitis
Meningitis
Pharmacokinetics
Ventriculitis
Journal
Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
pubmed:
5
1
2019
medline:
16
5
2020
entrez:
5
1
2019
Statut:
ppublish
Résumé
There are currently few data concerning the cerebrospinal fluid (CSF) penetration of daptomycin in patients with healthcare-associated meningitis. This study aims (1) to better characterize the pharmacokinetics of daptomycin in humans during a 7-day intravenous (IV) therapy course, and (2) to study the penetration of daptomycin in the CSF after IV infusion at the dose of 10 mg/kg. In this prospective observational study, we enrolled nine patients with an implanted external ventricular drainage and a diagnosis of a healthcare-associated meningitis. Daptomycin was administered at 10 mg/kg for a maximum of 7 days. The pharmacokinetic of daptomycin was studied using a two-compartment population/pharmacokinetic (POP/PK) model and by means of a nonlinear mixed effects modeling approach. A large inter-individual variability in plasma area under the curve (Range: 574.7-1366.3 h mg/L), paralleled by high-peak plasma concentration (C Our POP/PK model was able to describe the pharmacokinetics of daptomycin in both plasma and CSF, showing that daptomycin (up to 7 days at 10 mg/kg) has minimal penetration into central nervous system. Furthermore, the observed variability of AUC, t
Sections du résumé
BACKGROUND
There are currently few data concerning the cerebrospinal fluid (CSF) penetration of daptomycin in patients with healthcare-associated meningitis. This study aims (1) to better characterize the pharmacokinetics of daptomycin in humans during a 7-day intravenous (IV) therapy course, and (2) to study the penetration of daptomycin in the CSF after IV infusion at the dose of 10 mg/kg.
RESULTS
In this prospective observational study, we enrolled nine patients with an implanted external ventricular drainage and a diagnosis of a healthcare-associated meningitis. Daptomycin was administered at 10 mg/kg for a maximum of 7 days. The pharmacokinetic of daptomycin was studied using a two-compartment population/pharmacokinetic (POP/PK) model and by means of a nonlinear mixed effects modeling approach. A large inter-individual variability in plasma area under the curve (Range: 574.7-1366.3 h mg/L), paralleled by high-peak plasma concentration (C
CONCLUSIONS
Our POP/PK model was able to describe the pharmacokinetics of daptomycin in both plasma and CSF, showing that daptomycin (up to 7 days at 10 mg/kg) has minimal penetration into central nervous system. Furthermore, the observed variability of AUC, t
Identifiants
pubmed: 30607829
doi: 10.1007/s12028-018-0657-y
pii: 10.1007/s12028-018-0657-y
doi:
Substances chimiques
Anti-Bacterial Agents
0
Daptomycin
NWQ5N31VKK
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-124Références
Beer R, Lackner P, Pfausler B, Schmutzhard E. Nosocomial ventriculitis and meningitis in neurocritical care patients. J Neurol. 2008;255(11):1617–24.
doi: 10.1007/s00415-008-0059-8
pubmed: 19156484
Kitchen WJ, Singh N, Hulme S, Galea J, Patel HC, King AT. External ventricular drain infection: improved technique can reduce infection rates. Br J Neurosurg. 2011;25(5):632–5.
doi: 10.3109/02688697.2011.578770
pubmed: 21848440
Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2008;62(Suppl 2):688–700.
pubmed: 18596436
Korinek A-M, Baugnon T, Golmard J-L, van Effenterre R, Coriat P, Puybasset L. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery. 2008;62(Suppl 2):532–9.
pubmed: 18596451
Walti LN, Conen A, Coward J, Jost GF, Trampuz A. Characteristics of infections associated with external ventricular drains of cerebrospinal fluid. J Infect. 2013;66(5):424–31.
doi: 10.1016/j.jinf.2012.12.010
pubmed: 23313468
Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2002;51(1):170–2.
doi: 10.1097/00006123-200207000-00024
pubmed: 12182415
Camacho EF, Boszczowski I, Basso M, et al. Infection rate and risk factors associated with infections related to external ventricular drain. Infection. 2011;39(1):47–51.
doi: 10.1007/s15010-010-0073-5
pubmed: 21264679
Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg. 2003;98(5):1040–4.
doi: 10.3171/jns.2003.98.5.1040
pubmed: 12744364
Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64(6):701–6.
doi: 10.1093/cid/cix152
Pfausler B, Spiss H, Dittrich P, Zeitlinger M, Schmutzhard E, Joukhadar C. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother. 2004;53(5):848–52.
doi: 10.1093/jac/dkh158
pubmed: 15056646
Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother. 2007;51(1):379–82.
doi: 10.1128/AAC.00515-06
pubmed: 17043116
Malacarne P, Viaggi B, Di Paolo A, Danesi R, Del Tacca M. Linezolid cerebrospinal fluid concentration in central nervous system infection. J Chemother. 2007;19(1):90–3.
doi: 10.1179/joc.2007.19.1.90
pubmed: 17309857
Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother. 2006;50(12):3971–6.
doi: 10.1128/AAC.00051-06
pubmed: 16982782
pmcid: 1694012
Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother. 2007;41(2):296–308.
doi: 10.1345/aph.1H307
pubmed: 17284501
Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. Daptomycin 98-01 and 99-01 investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673–81.
doi: 10.1086/420818
pubmed: 15227611
Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.
doi: 10.1056/NEJMoa053783
pubmed: 16914701
Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology. 2008;81(2):79–91.
doi: 10.1159/000109868
pubmed: 17940348
Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3245–9.
doi: 10.1128/AAC.00247-06
pubmed: 17005801
pmcid: 1610083
Erritouni M, Ktaich N, Rahal JJ, et al. Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis. Case Rep Med. 2012;2012:593578.
doi: 10.1155/2012/593578
pubmed: 22649456
pmcid: 3357510
Kelesidis T, Humphries R, Ward K, Lewinski MA, Yang OO. Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagn Microbiol Infect Dis. 2011;71(3):286–90.
doi: 10.1016/j.diagmicrobio.2011.07.001
pubmed: 21855248
Le J, Bookstaver PB, Rudisill CN, et al. Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy. Ann Pharmacother. 2010;44(12):2001–6.
doi: 10.1345/aph.1P333
pubmed: 21119097
Vena A, Falcone M, Comandini E, et al. Daptomycin plus trimethoprim/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant Staphylococcus epidermidis. Diagn Microbiol Infect Dis. 2013;76(1):99–102.
doi: 10.1016/j.diagmicrobio.2013.01.021
pubmed: 23453066
Mueller SW, Kiser TH, Anderson TA, Neumann RT. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus Faecium. Ann Pharmacother. 2012;46(12):e35.
doi: 10.1345/aph.1R412
pubmed: 23232018
Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother. 2011;55(7):3505–9.
doi: 10.1128/AAC.01741-10
pubmed: 21502620
pmcid: 3122430
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.
doi: 10.1016/j.ajic.2008.03.002
pubmed: 18538699
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process . Accessed 20 Oct 2018.
Baietto L, D’Avolio A, De Rosa FG, et al. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Anal Bioanal Chem. 2010;396(2):791–8.
doi: 10.1007/s00216-009-3263-1
pubmed: 19898996
Baietto L, D’Avolio A, Pace S, et al. Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. J Pharm Biomed Anal. 2014;88:66–70.
doi: 10.1016/j.jpba.2013.08.022
pubmed: 24036034
https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf . Accessed 31 Oct 2018.
Di Paolo A, Tascini C, Polillo M, et al. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents. 2013;42(3):250–5.
doi: 10.1016/j.ijantimicag.2013.06.006
pubmed: 23891432
Di Paolo A, Gori G, Tascini C, Danesi R, Del Tacca M. Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. Clin Pharmacokinet. 2013;52(7):511–42.
doi: 10.1007/s40262-013-0062-9
pubmed: 23605634
Di Paolo A, Polillo M, Tascini C, Lewis R, Menichetti F, Danesi R. Different recommendations for daptomycin dosing over time in patients with severe infections. Clin Infect Dis. 2014;58(12):1788–9.
doi: 10.1093/cid/ciu230
pubmed: 24729499
Vivas M, Force E, Tubau F, El Haj C, Ariza J, Cabellos C. Effect of dexamethasone on the efficacy of daptomycin in the therapy of experimental pneumococcal meningitis. Int J Antimicrob Agents. 2015;46(1):28–32.
doi: 10.1016/j.ijantimicag.2015.01.014
pubmed: 25813395
Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57(11):1568–76.
doi: 10.1093/cid/cit582
Dvorchik B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol. 2004;44(7):715–22.
doi: 10.1177/0091270004266619
pubmed: 15199076